What is Bicara Therapeutics's operating lease liabilities?

Bicara Therapeutics (BCAX) reported operating lease liabilities of -$270K in Q1 2026.

How has Bicara Therapeutics's operating lease liabilities changed year-over-year?

Bicara Therapeutics's operating lease liabilities decreased by 83.7% year-over-year, from -$147K to -$270K.

Bicara Therapeutics BCAX Operating lease liabilities

Operating lease liabilities at other companies

ArriVent BioPharma, Inc.AVBP

——

ImmunomeIMNM

——

Vir Biotechnology, Inc.VIR

——

BridgeBio PharmaBBIO

——

Natera, Inc.NTRA

——

Aurinia PharmaceuticalsAUPH

——

Other financials

Income statement

See full

Operating income-$60.2M-44.2%

Net income-$56.2M-52.6%

EPS (diluted)-$0.93-36.8%

Balance sheet

See full

Cash & equivalents$323.5M-30.0%

Total debt$1.4M+144%

Total equity$514.0M+12.0%

Total assets$553.6M+15.8%

Cash flow

See full

Operating cash flow-$37.5M-33.5%

CapEx$60.0K—

Free cash flow-$37.6M-33.7%

Valuation

See full

Market cap$1.68B+81.4%

Returns & leverage

See full

Return on equity-32.3%—

Debt / equity0×0.0×

Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Bicara Therapeutics's operating lease liabilities?: Bicara Therapeutics (BCAX) reported operating lease liabilities of -$270K in Q1 2026.
How has Bicara Therapeutics's operating lease liabilities changed year-over-year?: Bicara Therapeutics's operating lease liabilities decreased by 83.7% year-over-year, from -$147K to -$270K.